SGLT2i and Cardiovascular Events in Patients With Concomitant Atrial Fibrillation and Diabetes: A TriNetX Cohort Study
Authors' conclusion
The use of SGLT2i was associated with reduced risks of stroke, dementia, long-standing persistent AF, heart failure, and mortality in patients with both AF and T2DM. SGLT2i may be considered as a potential first-line therapy for this population.
Study context
- Population
- Patients with concomitant atrial fibrillation (AF) and T2D from TriNetX; after propensity score matching (PSM) aged 68.4 ± 7.9 years17,011 per group after PSM
- Participants
- 339,792 patients
- Exposure
- SGLT2i use vs no SGLT2i use
- SGLT2in = 17,011
- Non-SGLT2in = 17,011reference
- Outcome
- Cardiovascular outcomes: stroke, dementia, long-standing persistent AF, HF, all-cause mortality
- Follow-up
- 3-year follow-up
Methodological detailspropensity-score matched (1:1), TriNetX international electronic medical record, multivariate Cox regression
- Propensity-score matched (1:1)
- TriNetX international electronic medical record
- Multivariate Cox regression
Main finding
As reported in the abstract
Cardiovascular outcomes · 3 years
- Stroke
- aHR 0.830; P < 0.001
- Dementia
- aHR 0.662; P < 0.001
- Long-standing persistent AF
- aHR 0.917; P < 0.001
- HF
- aHR 0.833; P < 0.001
- All-cause mortality
- aHR 0.532; P < 0.001
Observational data: associations, not effects.
Further findings
SGLT2i users before matching
- SGLT2i users among all patients
- 32 945 (9.70%)
Original publication
SGLT2i and Cardiovascular Events in Patients With Concomitant Atrial Fibrillation and Diabetes: A TriNetX Cohort Study. J Clin Endocrinol Metab. Published 25 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →